- Lobbying
- Lobbying by Model Medicines
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Adam Wilczewski | Chief of Staff, International Trade Administration |
Greg Goldner | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Amendment
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Supporting Model Medicines as it seeks federal funding to further develop, receive FDA approvals for, and begin manufacturing for their drug, MDL-001, which has been identified as a potential best-in-class, pan-antiviral drug with treatment paradigm changing potential. We are approachingcongressional committees that authorize and fund HHS/NIH programs and DARPA (at DOD). We also are approaching political appointees in thoseagencies, as possible..
Q4 Report
Registration
Issue(s) they said they’d lobby about: Supporting Model Medicines as it seeks federal funding to further develop, receive FDA approvals for, and begin manufacturing for their drug, MDL-001, which has been identified as a potential best-in-class, pan-antiviral drug with treatment paradigm changing potential.
We are approaching congressional committees that authorize and fund HHS/NIH programs and DARPA (at DOD). We also are approaching political appointees in those agencies, as possible..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate